Skip to content

A randomized controlled study of oxytocin nasal spray treatment for social disorders of Asperger's syndrome in early adulthood

A randomized controlled study of oxytocin nasal spray treatment for social disorders of Asperger's syndrome in early adulthood

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095220
Enrollment
Unknown
Registered
2025-01-03
Start date
2023-02-07
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asperger's syndrome

Interventions

Oxytocin group :AS patients in the oxytocin group were treated with oxytocin for 6 weeks at a daily dose of 48IU (24IU BID), and nasal spray was given to the patients twice a day in the morning and ev
Placebo group:AS patients in the placebo group were treated with placebo for 6 weeks at a daily dose of 48IU (24IU BID) and nasal spray twice a day in the morning and evening.

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for Asperger's syndrome in the American Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV); 2. 18 years old=85; 3. Gender is not limited; 4. Have not used any psychiatric medication in the three months prior to screening; 5. Able to complete all tests; 6. Informed consent of patients and guardians.

Exclusion criteria

Exclusion criteria: 1. Currently receiving psychiatric medication; 2. Subjects with a current or prior diagnosis of other disorders other than autism according to DSM-5 diagnostic criteria; 3. According to the clinical judgment of the investigator, subjects with severe impulsive aggression or self-injurious behavior, suicidal ideation and behavior; 4. Subject has a current or previous history of convulsive seizures (except for simple febrile seizures in childhood without sequelae); 5. Subjects with unstable physical illnesses requiring medical or surgical treatment; 6. Subjects with any anatomical or medical condition that may preclude intranasal administration or absorption of the study drug, as judged by the investigator clinically; 7. Subjects with abnormal clinical laboratory tests or electrocardiogram examinations and clinical significance during the screening period; 8. Subjects with known allergies to oxytocin or the main components of oxytocin nasal spray.

Design outcomes

Primary

MeasureTime frame
SRS scale total score change value;Change in total score of CSQ scale;

Secondary

MeasureTime frame
The change value of the total score of RBS scale;1. Brain activation: fMRI data under the task were detected and analyzed to determine the similarities and differences of brain activation patterns between the two groups of patients under the empathy-systematization task. ;2. Brain functional connectivity: psychophysiological interaction analysis was used to study whether the functional interaction between the interested brain area and other brain areas in the whole brain found in the empathy-systematization level task was regulated by the task state;3. Brain effect linkage: Based on the previous analysis results, a dynamic causal model was used to establish a directed interaction model of brain function under the empathic-systematic level task, and the differences in effect linkage patterns between the two groups were compared.;

Countries

China

Contacts

Public ContactTian Yin

Beijing Anding Hospital Affiliated to Capital Medical University

tianyin326@163.com+86 159 0158 2011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026